Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Health-related quality of life in patients with acute promyelocytic leukemia: a systematic literature review EXPERT REVIEW OF HEMATOLOGY 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network FRONTIERS IN ONCOLOGY 2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols ACTA ONCOLOGICA 2021
Asciminib Provides Durable Responses and a Favorable Safety Profile in Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with the T315I Mutation in a Phase 1 Study CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2021
Effect of Comorbidities on Response Outcomes with First-Line Tyrosine Kinase Inhibitors (TKIs), Dasatinib Versus Imatinib, in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Post Hoc Analysis of DASISION CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2021
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study ACTA ONCOLOGICA 2021
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios CANCERS 2021
Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy BLOOD ADVANCES 2021
Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea BLOOD 2021
Peripheral Blasts Are Associated with Response to Ruxolitinib and Outcome in Patients with Chronic-Phase Myelofibrosis BLOOD 2021
Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A ``Campus CML{''} Study BLOOD 2021
Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) BLOOD 2021
Very late acute myeloid leukemia relapse: clinical features, treatment and outcome LEUKEMIA & LYMPHOMA 2021
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment HEMATOLOGICAL ONCOLOGY 2020
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants AMERICAN JOURNAL OF THERAPEUTICS 2020
Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia EUROPEAN JOURNAL OF HAEMATOLOGY 2020
Outcomes of long‐term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 2020
Direct Oral Anticoagulants In Patients With Hematologic Malignancies HEMATOLOGICAL ONCOLOGY 2020
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms AMERICAN JOURNAL OF HEMATOLOGY 2020
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors CLINICAL DRUG INVESTIGATION 2020

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma